nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—CYP1A2—Imiquimod—skin cancer	0.0992	0.125	CbGbCtD
Dapagliflozin—CYP1A1—Dacarbazine—skin cancer	0.0933	0.118	CbGbCtD
Dapagliflozin—CYP2A6—Fluorouracil—skin cancer	0.064	0.0808	CbGbCtD
Dapagliflozin—CYP2C9—Vismodegib—skin cancer	0.062	0.0782	CbGbCtD
Dapagliflozin—ABCB1—Vismodegib—skin cancer	0.0601	0.0759	CbGbCtD
Dapagliflozin—CYP1A2—Vemurafenib—skin cancer	0.0544	0.0686	CbGbCtD
Dapagliflozin—CYP3A4—Imiquimod—skin cancer	0.052	0.0656	CbGbCtD
Dapagliflozin—CYP3A4—Temozolomide—skin cancer	0.052	0.0656	CbGbCtD
Dapagliflozin—CYP2D6—Vemurafenib—skin cancer	0.0448	0.0566	CbGbCtD
Dapagliflozin—CYP1A2—Dacarbazine—skin cancer	0.0417	0.0526	CbGbCtD
Dapagliflozin—CYP3A4—Vismodegib—skin cancer	0.036	0.0455	CbGbCtD
Dapagliflozin—ABCB1—Dactinomycin—skin cancer	0.0316	0.0399	CbGbCtD
Dapagliflozin—CYP3A4—Vemurafenib—skin cancer	0.0285	0.036	CbGbCtD
Dapagliflozin—Vaginitis bacterial—Imiquimod—skin cancer	0.0285	0.137	CcSEcCtD
Dapagliflozin—Vulvitis—Imiquimod—skin cancer	0.0246	0.118	CcSEcCtD
Dapagliflozin—CYP1A2—Fluorouracil—skin cancer	0.0244	0.0308	CbGbCtD
Dapagliflozin—CYP2C9—Fluorouracil—skin cancer	0.022	0.0278	CbGbCtD
Dapagliflozin—ABCB1—Docetaxel—skin cancer	0.0163	0.0206	CbGbCtD
Dapagliflozin—CYP3A4—Docetaxel—skin cancer	0.00977	0.0123	CbGbCtD
Dapagliflozin—Genital candidiasis—Imiquimod—skin cancer	0.00939	0.0451	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Vismodegib—skin cancer	0.00456	0.0219	CcSEcCtD
Dapagliflozin—Blood urea increased—Vismodegib—skin cancer	0.00368	0.0177	CcSEcCtD
Dapagliflozin—Angina unstable—Docetaxel—skin cancer	0.00324	0.0155	CcSEcCtD
Dapagliflozin—Hyponatraemia—Vismodegib—skin cancer	0.00284	0.0136	CcSEcCtD
Dapagliflozin—Pain in extremity—Vismodegib—skin cancer	0.00283	0.0136	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Vemurafenib—skin cancer	0.00282	0.0135	CcSEcCtD
Dapagliflozin—Fungal infection—Imiquimod—skin cancer	0.00266	0.0128	CcSEcCtD
Dapagliflozin—Dehydration—Vismodegib—skin cancer	0.00263	0.0126	CcSEcCtD
Dapagliflozin—Neoplasm—Vemurafenib—skin cancer	0.00217	0.0104	CcSEcCtD
Dapagliflozin—Vaginal infection—Imiquimod—skin cancer	0.00194	0.0093	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Vismodegib—skin cancer	0.00192	0.00923	CcSEcCtD
Dapagliflozin—Pain in extremity—Vemurafenib—skin cancer	0.00175	0.00839	CcSEcCtD
Dapagliflozin—Lung disorder—Temozolomide—skin cancer	0.00174	0.00834	CcSEcCtD
Dapagliflozin—Malnutrition—Vismodegib—skin cancer	0.0017	0.00818	CcSEcCtD
Dapagliflozin—Extravasation—Bleomycin—skin cancer	0.00167	0.00803	CcSEcCtD
Dapagliflozin—Back pain—Vismodegib—skin cancer	0.00165	0.00791	CcSEcCtD
Dapagliflozin—Extravasation—Dactinomycin—skin cancer	0.00156	0.00748	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Imiquimod—skin cancer	0.00152	0.0073	CcSEcCtD
Dapagliflozin—Pain in extremity—Imiquimod—skin cancer	0.00149	0.00715	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00144	0.00691	CcSEcCtD
Dapagliflozin—Skin disorder—Vismodegib—skin cancer	0.00135	0.00648	CcSEcCtD
Dapagliflozin—Infestation NOS—Vemurafenib—skin cancer	0.00135	0.00646	CcSEcCtD
Dapagliflozin—Infestation—Vemurafenib—skin cancer	0.00135	0.00646	CcSEcCtD
Dapagliflozin—Extravasation—Fluorouracil—skin cancer	0.0013	0.00624	CcSEcCtD
Dapagliflozin—Influenza—Imiquimod—skin cancer	0.00129	0.00618	CcSEcCtD
Dapagliflozin—Phlebitis—Bleomycin—skin cancer	0.00123	0.0059	CcSEcCtD
Dapagliflozin—Dysuria—Imiquimod—skin cancer	0.0012	0.00578	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Vismodegib—skin cancer	0.0012	0.00576	CcSEcCtD
Dapagliflozin—Constipation—Vismodegib—skin cancer	0.00119	0.00571	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Vemurafenib—skin cancer	0.00119	0.0057	CcSEcCtD
Dapagliflozin—Vaginal infection—Temozolomide—skin cancer	0.00116	0.00558	CcSEcCtD
Dapagliflozin—Infestation NOS—Imiquimod—skin cancer	0.00115	0.00551	CcSEcCtD
Dapagliflozin—Infestation—Imiquimod—skin cancer	0.00115	0.00551	CcSEcCtD
Dapagliflozin—Phlebitis—Dactinomycin—skin cancer	0.00115	0.0055	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Imiquimod—skin cancer	0.00113	0.00544	CcSEcCtD
Dapagliflozin—Myocardial infarction—Imiquimod—skin cancer	0.00112	0.0054	CcSEcCtD
Dapagliflozin—Urinary tract infection—Imiquimod—skin cancer	0.00112	0.00536	CcSEcCtD
Dapagliflozin—Neoplasm—Temozolomide—skin cancer	0.00111	0.00534	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Bleomycin—skin cancer	0.00108	0.00519	CcSEcCtD
Dapagliflozin—Malnutrition—Vemurafenib—skin cancer	0.00105	0.00505	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Imiquimod—skin cancer	0.00102	0.00489	CcSEcCtD
Dapagliflozin—Back pain—Vemurafenib—skin cancer	0.00102	0.00489	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Imiquimod—skin cancer	0.00101	0.00486	CcSEcCtD
Dapagliflozin—Urethral disorder—Imiquimod—skin cancer	0.00101	0.00485	CcSEcCtD
Dapagliflozin—Thirst—Temozolomide—skin cancer	0.000938	0.00451	CcSEcCtD
Dapagliflozin—Extravasation—Docetaxel—skin cancer	0.000937	0.0045	CcSEcCtD
Dapagliflozin—Malnutrition—Imiquimod—skin cancer	0.000897	0.00431	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000889	0.00427	CcSEcCtD
Dapagliflozin—Rash—Vismodegib—skin cancer	0.000876	0.00421	CcSEcCtD
Dapagliflozin—Dermatitis—Vismodegib—skin cancer	0.000875	0.0042	CcSEcCtD
Dapagliflozin—Back pain—Imiquimod—skin cancer	0.000867	0.00417	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Vemurafenib—skin cancer	0.000858	0.00412	CcSEcCtD
Dapagliflozin—Infection—Vemurafenib—skin cancer	0.000852	0.0041	CcSEcCtD
Dapagliflozin—Skin disorder—Vemurafenib—skin cancer	0.000833	0.004	CcSEcCtD
Dapagliflozin—Dehydration—Temozolomide—skin cancer	0.00083	0.00399	CcSEcCtD
Dapagliflozin—Nausea—Vismodegib—skin cancer	0.000825	0.00396	CcSEcCtD
Dapagliflozin—Angioedema—Imiquimod—skin cancer	0.000819	0.00394	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Bleomycin—skin cancer	0.000804	0.00386	CcSEcCtD
Dapagliflozin—Hypotension—Vemurafenib—skin cancer	0.000802	0.00385	CcSEcCtD
Dapagliflozin—Myocardial infarction—Bleomycin—skin cancer	0.000799	0.00384	CcSEcCtD
Dapagliflozin—Hypertension—Imiquimod—skin cancer	0.000774	0.00372	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000758	0.00364	CcSEcCtD
Dapagliflozin—Discomfort—Imiquimod—skin cancer	0.000754	0.00362	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000741	0.00356	CcSEcCtD
Dapagliflozin—Neoplasm—Docetaxel—skin cancer	0.000739	0.00355	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Fluorouracil—skin cancer	0.000735	0.00353	CcSEcCtD
Dapagliflozin—Constipation—Vemurafenib—skin cancer	0.000734	0.00353	CcSEcCtD
Dapagliflozin—Oedema—Imiquimod—skin cancer	0.000732	0.00352	CcSEcCtD
Dapagliflozin—Infection—Imiquimod—skin cancer	0.000727	0.00349	CcSEcCtD
Dapagliflozin—Dysuria—Temozolomide—skin cancer	0.000721	0.00347	CcSEcCtD
Dapagliflozin—Pollakiuria—Temozolomide—skin cancer	0.000712	0.00342	CcSEcCtD
Dapagliflozin—Skin disorder—Imiquimod—skin cancer	0.000711	0.00342	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Imiquimod—skin cancer	0.000707	0.0034	CcSEcCtD
Dapagliflozin—Angina pectoris—Fluorouracil—skin cancer	0.000692	0.00333	CcSEcCtD
Dapagliflozin—Phlebitis—Docetaxel—skin cancer	0.000689	0.00331	CcSEcCtD
Dapagliflozin—Infestation NOS—Temozolomide—skin cancer	0.000688	0.0033	CcSEcCtD
Dapagliflozin—Infestation—Temozolomide—skin cancer	0.000688	0.0033	CcSEcCtD
Dapagliflozin—Body temperature increased—Vemurafenib—skin cancer	0.000678	0.00326	CcSEcCtD
Dapagliflozin—Urinary tract infection—Temozolomide—skin cancer	0.000668	0.00321	CcSEcCtD
Dapagliflozin—Infestation—Fluorouracil—skin cancer	0.000634	0.00304	CcSEcCtD
Dapagliflozin—Infestation NOS—Fluorouracil—skin cancer	0.000634	0.00304	CcSEcCtD
Dapagliflozin—Hypersensitivity—Vemurafenib—skin cancer	0.000632	0.00304	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Imiquimod—skin cancer	0.000632	0.00304	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Fluorouracil—skin cancer	0.000625	0.003	CcSEcCtD
Dapagliflozin—Myocardial infarction—Fluorouracil—skin cancer	0.000621	0.00298	CcSEcCtD
Dapagliflozin—Urinary tract infection—Fluorouracil—skin cancer	0.000616	0.00296	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Temozolomide—skin cancer	0.00061	0.00293	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Temozolomide—skin cancer	0.000607	0.00291	CcSEcCtD
Dapagliflozin—Urethral disorder—Temozolomide—skin cancer	0.000605	0.00291	CcSEcCtD
Dapagliflozin—Hyponatraemia—Docetaxel—skin cancer	0.000596	0.00286	CcSEcCtD
Dapagliflozin—Pain in extremity—Docetaxel—skin cancer	0.000593	0.00285	CcSEcCtD
Dapagliflozin—Urticaria—Imiquimod—skin cancer	0.000581	0.00279	CcSEcCtD
Dapagliflozin—Body temperature increased—Imiquimod—skin cancer	0.000578	0.00278	CcSEcCtD
Dapagliflozin—Dizziness—Vemurafenib—skin cancer	0.000567	0.00273	CcSEcCtD
Dapagliflozin—Dehydration—Docetaxel—skin cancer	0.000552	0.00265	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Docetaxel—skin cancer	0.000542	0.0026	CcSEcCtD
Dapagliflozin—Rash—Vemurafenib—skin cancer	0.000541	0.0026	CcSEcCtD
Dapagliflozin—Dermatitis—Vemurafenib—skin cancer	0.000541	0.0026	CcSEcCtD
Dapagliflozin—Hypersensitivity—Imiquimod—skin cancer	0.000539	0.00259	CcSEcCtD
Dapagliflozin—Headache—Vemurafenib—skin cancer	0.000538	0.00258	CcSEcCtD
Dapagliflozin—Malnutrition—Temozolomide—skin cancer	0.000537	0.00258	CcSEcCtD
Dapagliflozin—Discomfort—Bleomycin—skin cancer	0.000536	0.00257	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Docetaxel—skin cancer	0.000531	0.00255	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Bleomycin—skin cancer	0.00052	0.0025	CcSEcCtD
Dapagliflozin—Oedema—Bleomycin—skin cancer	0.00052	0.0025	CcSEcCtD
Dapagliflozin—Back pain—Temozolomide—skin cancer	0.00052	0.0025	CcSEcCtD
Dapagliflozin—Infection—Bleomycin—skin cancer	0.000516	0.00248	CcSEcCtD
Dapagliflozin—Nausea—Vemurafenib—skin cancer	0.00051	0.00245	CcSEcCtD
Dapagliflozin—Discomfort—Dactinomycin—skin cancer	0.0005	0.0024	CcSEcCtD
Dapagliflozin—Angina pectoris—Docetaxel—skin cancer	0.0005	0.0024	CcSEcCtD
Dapagliflozin—Angioedema—Temozolomide—skin cancer	0.000491	0.00236	CcSEcCtD
Dapagliflozin—Hypotension—Bleomycin—skin cancer	0.000486	0.00233	CcSEcCtD
Dapagliflozin—Oedema—Dactinomycin—skin cancer	0.000485	0.00233	CcSEcCtD
Dapagliflozin—Dizziness—Imiquimod—skin cancer	0.000484	0.00233	CcSEcCtD
Dapagliflozin—Infection—Dactinomycin—skin cancer	0.000482	0.00231	CcSEcCtD
Dapagliflozin—Hypertension—Temozolomide—skin cancer	0.000464	0.00223	CcSEcCtD
Dapagliflozin—Rash—Imiquimod—skin cancer	0.000461	0.00222	CcSEcCtD
Dapagliflozin—Dermatitis—Imiquimod—skin cancer	0.000461	0.00222	CcSEcCtD
Dapagliflozin—Headache—Imiquimod—skin cancer	0.000458	0.0022	CcSEcCtD
Dapagliflozin—Infestation—Docetaxel—skin cancer	0.000457	0.0022	CcSEcCtD
Dapagliflozin—Infestation NOS—Docetaxel—skin cancer	0.000457	0.0022	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000454	0.00218	CcSEcCtD
Dapagliflozin—Discomfort—Temozolomide—skin cancer	0.000452	0.00217	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Docetaxel—skin cancer	0.000451	0.00217	CcSEcCtD
Dapagliflozin—Renal failure—Docetaxel—skin cancer	0.000449	0.00216	CcSEcCtD
Dapagliflozin—Myocardial infarction—Docetaxel—skin cancer	0.000448	0.00215	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Temozolomide—skin cancer	0.000439	0.00211	CcSEcCtD
Dapagliflozin—Oedema—Temozolomide—skin cancer	0.000439	0.00211	CcSEcCtD
Dapagliflozin—Infection—Temozolomide—skin cancer	0.000436	0.00209	CcSEcCtD
Dapagliflozin—Nausea—Imiquimod—skin cancer	0.000435	0.00209	CcSEcCtD
Dapagliflozin—Skin disorder—Temozolomide—skin cancer	0.000426	0.00205	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Temozolomide—skin cancer	0.000424	0.00204	CcSEcCtD
Dapagliflozin—Discomfort—Fluorouracil—skin cancer	0.000416	0.002	CcSEcCtD
Dapagliflozin—Urticaria—Bleomycin—skin cancer	0.000413	0.00198	CcSEcCtD
Dapagliflozin—Body temperature increased—Bleomycin—skin cancer	0.000411	0.00197	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Docetaxel—skin cancer	0.000405	0.00195	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Fluorouracil—skin cancer	0.000404	0.00194	CcSEcCtD
Dapagliflozin—Oedema—Fluorouracil—skin cancer	0.000404	0.00194	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Docetaxel—skin cancer	0.000403	0.00194	CcSEcCtD
Dapagliflozin—Urethral disorder—Docetaxel—skin cancer	0.000402	0.00193	CcSEcCtD
Dapagliflozin—Infection—Fluorouracil—skin cancer	0.000401	0.00193	CcSEcCtD
Dapagliflozin—Body temperature increased—Dactinomycin—skin cancer	0.000383	0.00184	CcSEcCtD
Dapagliflozin—Hypersensitivity—Bleomycin—skin cancer	0.000383	0.00184	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Temozolomide—skin cancer	0.000379	0.00182	CcSEcCtD
Dapagliflozin—Hypotension—Fluorouracil—skin cancer	0.000378	0.00181	CcSEcCtD
Dapagliflozin—Constipation—Temozolomide—skin cancer	0.000375	0.0018	CcSEcCtD
Dapagliflozin—Malnutrition—Docetaxel—skin cancer	0.000357	0.00172	CcSEcCtD
Dapagliflozin—Hypersensitivity—Dactinomycin—skin cancer	0.000357	0.00172	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000349	0.00168	CcSEcCtD
Dapagliflozin—Urticaria—Temozolomide—skin cancer	0.000348	0.00167	CcSEcCtD
Dapagliflozin—Body temperature increased—Temozolomide—skin cancer	0.000347	0.00167	CcSEcCtD
Dapagliflozin—Back pain—Docetaxel—skin cancer	0.000346	0.00166	CcSEcCtD
Dapagliflozin—Rash—Bleomycin—skin cancer	0.000328	0.00158	CcSEcCtD
Dapagliflozin—Dermatitis—Bleomycin—skin cancer	0.000327	0.00157	CcSEcCtD
Dapagliflozin—Hypersensitivity—Temozolomide—skin cancer	0.000323	0.00155	CcSEcCtD
Dapagliflozin—Urticaria—Fluorouracil—skin cancer	0.000321	0.00154	CcSEcCtD
Dapagliflozin—Body temperature increased—Fluorouracil—skin cancer	0.000319	0.00153	CcSEcCtD
Dapagliflozin—Nausea—Bleomycin—skin cancer	0.000309	0.00148	CcSEcCtD
Dapagliflozin—Hypertension—Docetaxel—skin cancer	0.000309	0.00148	CcSEcCtD
Dapagliflozin—Rash—Dactinomycin—skin cancer	0.000306	0.00147	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000302	0.00145	CcSEcCtD
Dapagliflozin—Hypersensitivity—Fluorouracil—skin cancer	0.000298	0.00143	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Docetaxel—skin cancer	0.000292	0.0014	CcSEcCtD
Dapagliflozin—Oedema—Docetaxel—skin cancer	0.000292	0.0014	CcSEcCtD
Dapagliflozin—Dizziness—Temozolomide—skin cancer	0.00029	0.00139	CcSEcCtD
Dapagliflozin—Infection—Docetaxel—skin cancer	0.00029	0.00139	CcSEcCtD
Dapagliflozin—Nausea—Dactinomycin—skin cancer	0.000288	0.00138	CcSEcCtD
Dapagliflozin—Skin disorder—Docetaxel—skin cancer	0.000283	0.00136	CcSEcCtD
Dapagliflozin—Rash—Temozolomide—skin cancer	0.000276	0.00133	CcSEcCtD
Dapagliflozin—Dermatitis—Temozolomide—skin cancer	0.000276	0.00133	CcSEcCtD
Dapagliflozin—Headache—Temozolomide—skin cancer	0.000275	0.00132	CcSEcCtD
Dapagliflozin—Hypotension—Docetaxel—skin cancer	0.000273	0.00131	CcSEcCtD
Dapagliflozin—Dizziness—Fluorouracil—skin cancer	0.000267	0.00128	CcSEcCtD
Dapagliflozin—Nausea—Temozolomide—skin cancer	0.00026	0.00125	CcSEcCtD
Dapagliflozin—Rash—Fluorouracil—skin cancer	0.000255	0.00122	CcSEcCtD
Dapagliflozin—Dermatitis—Fluorouracil—skin cancer	0.000255	0.00122	CcSEcCtD
Dapagliflozin—Headache—Fluorouracil—skin cancer	0.000253	0.00122	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Docetaxel—skin cancer	0.000252	0.00121	CcSEcCtD
Dapagliflozin—Constipation—Docetaxel—skin cancer	0.000249	0.0012	CcSEcCtD
Dapagliflozin—Nausea—Fluorouracil—skin cancer	0.00024	0.00115	CcSEcCtD
Dapagliflozin—Body temperature increased—Docetaxel—skin cancer	0.000231	0.00111	CcSEcCtD
Dapagliflozin—Hypersensitivity—Docetaxel—skin cancer	0.000215	0.00103	CcSEcCtD
Dapagliflozin—Dizziness—Docetaxel—skin cancer	0.000193	0.000927	CcSEcCtD
Dapagliflozin—Rash—Docetaxel—skin cancer	0.000184	0.000884	CcSEcCtD
Dapagliflozin—Dermatitis—Docetaxel—skin cancer	0.000184	0.000883	CcSEcCtD
Dapagliflozin—Headache—Docetaxel—skin cancer	0.000183	0.000878	CcSEcCtD
Dapagliflozin—Nausea—Docetaxel—skin cancer	0.000173	0.000832	CcSEcCtD
